Vidal A M, Chéron G, Rey E, Pons G, d'Athis P, Olive G
Département de Pharmacologie Périnatale et Pédiatrique, Hôpital Saint-Vincent de Paul, Paris, France.
Eur J Clin Pharmacol. 1993;45(1):89-91. doi: 10.1007/BF00315356.
The pharmacokinetics of diphemanil methylsulphate was evaluated after oral administration of a single 3 mg.kg-1 dose to 5 infants being treated for symptomatic bradycardia. The mean pharmacokinetic parameters of oral diphemanil methylsulphate in infants were similar to those in adults. The mean half-life was 8.6 h. This would allow administration three times a day in infants instead of four to six times a day, as currently prescribed. The mean residence time decreases significantly with age (Spearman's r' = -1), and there is a trend for the half-life to decrease with age (r' = -0.9; NS), suggesting an influence of maturation on its elimination.
对5名因症状性心动过缓接受治疗的婴儿口服3mg·kg-1单剂量的甲硫酸地芬尼后,评估了其药代动力学。婴儿口服甲硫酸地芬尼的平均药代动力学参数与成人相似。平均半衰期为8.6小时。这将允许婴儿每日给药3次,而非目前规定的每日4至6次。平均驻留时间随年龄显著降低(斯皮尔曼相关系数r' = -1),且半衰期有随年龄降低的趋势(r' = -0.9;无统计学意义),提示成熟对其消除有影响。